Advertisement

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Josh Lehrer-Graiwer, Jo Howard, Claire Jane Hemmaway, Moji Awogbade, Paul Telfer, Mark Layton, Timothy Mant, Kobina Dufu, Athiwat Hutchaleelaha, Teri Koller, Donna Oksenberg, Mira Patel and Eleanor Ramos

Article Information

Citation 
vol. 126 no. 23 542

Print ISSN 
Online ISSN 
History 
  • Published online December 3, 2015.


Contributors 
  • Josh Lehrer-Graiwer [MDMPhil, FACC], 1Global Blood Therapeutics, South San Francisco, CA
  • Jo Howard [MD], 2Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
  • Claire Jane Hemmaway [MD], 3ba, Romford, United Kingdom
  • Moji Awogbade, 4Department of Haematology, King's College Hospital, London, United Kingdom
  • Paul Telfer [FRCPath,MD], 5The Royal London Hospital, London, United Kingdom
  • Mark Layton [MB, FRCP], 6Imperial College NHS Foundation Trust, London, United Kingdom
  • Timothy Mant [MB, FFPM, FRCP], 7Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom
  • Kobina Dufu [PhD], 1Global Blood Therapeutics, South San Francisco, CA
  • Athiwat Hutchaleelaha [PhD], 1Global Blood Therapeutics, South San Francisco, CA
  • Teri Koller [MBA], 1Global Blood Therapeutics, South San Francisco, CA
  • Donna Oksenberg [PhD], 1Global Blood Therapeutics, South San Francisco, CA
  • Mira Patel [PhD], 1Global Blood Therapeutics, South San Francisco, CA
  • Eleanor Ramos [MD], 1Global Blood Therapeutics, South San Francisco, CA

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output